Remus Pharmaceuticals Ltd.

As of March 31, 2026, Remus Pharmaceuticals Ltd. carries a market capitalization of 7.40B, placing it among publicly traded companies globally. Its enterprise value stands at 7.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Remus Pharmaceuticals Ltd. has 11.78M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Remus Pharmaceuticals Ltd. maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Remus Pharmaceuticals Ltd. recorded 66.80M in income tax expense.

As of the close on October 22, 2026, Remus Pharmaceuticals Ltd.'s stock has gained approximately 32.54% over the past 52 weeks. The 50-day moving average sits at 917.95, while the 200-day moving average is 759.27.

As of March 31, 2026, Remus Pharmaceuticals Ltd. holds 549.10M in cash and equivalents against 270.70M in total debt, resulting in a net debt position of 112.20M. Total book value stands at 3.51B, with working capital of 1.46B providing operational flexibility.

Remus Pharmaceuticals Ltd.'s most recent stock split took place on July 4, 2025 with a 1:2 split ratio.